Osmotica Pharmaceuticals (NASDAQ:OSMT) Downgraded by Zacks Investment Research to Sell

Osmotica Pharmaceuticals stock has undergone multiple analysts rating changes in the recent past.  Osmotica Pharmaceuticals Downgraded by Zacks Investment Research on 10/14/2021. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

Shares of Osmotica Pharmaceuticals traded down -$0.04 on Wednesday, reaching $2.01. 4219 shares of the stock traded hands, compared to its average volume of 999226. Shares of Osmotica Pharmaceuticals were trading at $2.01 on Wednesday. The firm’s 50 day moving average is $3.23 and its 200 day moving average is $3.47.Osmotica Pharmaceuticals has a 12 month low of $1.93 and a 12 month high of $6.38. While on yearly highs and lows, Osmotica Pharmaceuticals’s today has traded high as $2.08 and has touched $1.93 on the downward trend. See More Analyst Rating at: RATING

Osmotica Pharmaceuticals Earnings and What to expect: 

Osmotica Pharmaceuticals last issued its earnings data on August 16th, 2021. The reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by $0.14. The firm had revenue of $11.51 million for the quarter, compared to analysts’ expectations of $34.50 million. Osmotica Pharmaceuticals has generated ($0.37) earnings per share over the last year (($1.45) diluted earnings per share). Earnings for Osmotica Pharmaceuticals are expected to grow in the coming year, from ($0.89) to ($0.60) per share. Osmotica Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, November 9th, 2021 based off prior year’s report dates.

Earnings for Osmotica Pharmaceuticals are expected to grow in the coming year, from ($0.89) to ($0.60) per share. The P/E ratio of Osmotica Pharmaceuticals is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Osmotica Pharmaceuticals is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Osmotica Pharmaceuticals has a P/B Ratio of 1.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Osmotica Pharmaceuticals (NASDAQ:OSMT) Moving Average Technical Analysis

5 day Moving Average is $1.95 And 5 day price change is -$1.05 (-34.31%)  with average volume for 5 day average is 5,451,740. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $2.72 and 20 day price change is -$0.95 (-32.09%) and average 20 day moving volume is 1,483,725. 50 day moving average is $3.23  and 50 day price change is -$1.54 ( -43.38%)  and with average volume for 50 days is : 703,970. 200 day moving average is $3.47  and 200 day price change is -$3.86 (-65.76%)  and with average volume for 200 days is : 778,159.

Other owners latest trading in Osmotica Pharmaceuticals :

  • On 8/25/2021 shares held by Marshall Wace LLP were 57,958 which equates to market value of $0.17M and appx 0.00% owners of Osmotica Pharmaceuticals
  • On 8/23/2021 shares held by Morgan Stanley were 1,668,651 which equates to market value of $5.02M and appx 0.00% owners of Osmotica Pharmaceuticals
  • On 8/17/2021 shares held by Millennium Management LLC were 160,140 which equates to market value of $0.48M and appx 0.00% owners of Osmotica Pharmaceuticals
  • In total Institutional ownership equates to Institutional Ownership Percentage: 7.71% for Osmotica Pharmaceuticals

See More Analyst Rating at: RATING